Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia

BACKGROUND: UCART19 is an “off-the-shelf” genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells. METHODS: UCART19 was administered to 25 adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupouy, Sandra, Marchiq, Ibtissam, Derippe, Thibaud, Almena-Carrasco, Maria, Jozwik, Agnieszka, Fouliard, Sylvain, Adimy, Yasmina, Geronimi, Julia, Graham, Charlotte, Jain, Nitin, Maus, Marcela V., Mohty, Mohamad, Boissel, Nicolas, Teshima, Takanori, Kato, Koji, Benjamin, Reuben, Balandraud, Svetlana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035397/
https://www.ncbi.nlm.nih.gov/pubmed/36970059
http://dx.doi.org/10.1158/2767-9764.CRC-22-0175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035397/
https://www.ncbi.nlm.nih.gov/pubmed/36970059
http://dx.doi.org/10.1158/2767-9764.CRC-22-0175

Ejemplares similares